---
audienceLevel: patient
cancerTypes:
- general
citation: NCI, 2025
language: en
lastReviewed: '2025-12-30'
license: public_domain
reviewFrequency: quarterly
source: NCI
sourceType: 02_nci_core
status: active
tags:
- treatment
title: Ruxolitinib Phosphate - NCI
url: https://www.cancer.gov/about-cancer/treatment/drugs/ruxolitinibphosphate
version: v1
---

# Ruxolitinib Phosphate - NCI

# Ruxolitinib Phosphate

Placeholder slot

(RUK-soh-LIH-tih-nib FOS-fayt)

This page contains brief information about ruxolitinib phosphate and a collection of links to more information about the use of
this drug, research results, and ongoing clinical trials.

US Brand Name(s)

Jakafi

FDA Approved

Yes

[FDA label information for this drug is available at DailyMed.](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1c82580-87ae-11e0-bc84-0002a5d5c51b&audience=consumer)

## Use in Cancer

Ruxolitinib phosphate
is approved
for use in adults to treat:

- **[myelofibrosis](/Common/PopUps/popDefinition.aspx?id=45947&version=Patient&language=English)** (a [bone marrow](/Common/PopUps/popDefinition.aspx?id=45622&version=Patient&language=English) disease) that is intermediate risk or high risk, including the following types:
- [primary myelofibrosis](/Common/PopUps/popDefinition.aspx?id=306488&version=Patient&language=English)
- post-[polycythemia vera](/Common/PopUps/popDefinition.aspx?id=426418&version=Patient&language=English) myelofibrosis
- post-[essential thrombocythemia](/Common/PopUps/popDefinition.aspx?id=256562&version=Patient&language=English) myelofibrosis
- **polycythemia vera** in patients who cannot be treated with or have not gotten better with [hydroxyurea](/Common/PopUps/popDefinition.aspx?id=45308&version=Patient&language=English)

Ruxolitinib phosphate
is also being studied in the treatment of some types of
cancer.

## More About Ruxolitinib Phosphate

[Definition from the NCI Drug Dictionary](https://www.cancer.gov/publications/dictionaries/cancer-drug/def/593437) - Detailed scientific definition and other names for this drug.

MedlinePlus Information on [Ruxolitinib Phosphate](https://medlineplus.gov/druginfo/meds/a612006.html) - A lay language summary of important information about this drug that may include the following:

- warnings about this drug,
- what this drug is used for and how it is used,
- what you should tell your doctor before using this drug,
- what you should know about this drug before using it,
- other drugs that may interact with this drug, and
- possible side effects.

Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.

## Research Results and Related Resources

[Drug Combo JAKs Up Immunotherapy in Two Clinical Trials](https://www.cancer.gov/news-events/cancer-currents-blog/2024/jak-inhibitor-improves-cancer-immunotherapy)

[Targeted Therapy to Treat Cancer](https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies)

## Clinical Trials Accepting Patients

[Find Clinical Trials for Ruxolitinib Phosphate](https://www.cancer.gov/research/participate/clinical-trials/intervention/C97937) - Check for trials from NCI's list of cancer clinical trials now accepting patients.
